Deciphera Pharmaceuticals, Inc. (DCPH)

NASDAQ: DCPH · IEX Real-Time Price · USD
15.02
-0.63 (-4.03%)
Dec 5, 2022 4:00 PM EST - Market closed
-4.03%
Market Cap 1.06B
Revenue (ttm) 121.89M
Net Income (ttm) -221.39M
Shares Out 78.21M
EPS (ttm) -4.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,258,554
Open 15.63
Previous Close 15.65
Day's Range 14.73 - 15.63
52-Week Range 6.51 - 20.88
Beta 0.77
Analysts Buy
Price Target 19.02 (+26.6%)
Earnings Date Nov 3, 2022

About DCPH

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switc... [Read more]

Industry Biotechnology
IPO Date Sep 28, 2017
CEO Steven Hoerter
Employees 280
Stock Exchange NASDAQ
Ticker Symbol DCPH
Full Company Profile

Financial Performance

In 2021, DCPH's revenue was $96.15 million, an increase of 128.45% compared to the previous year's $42.09 million. Losses were -$299.96 million, 12.6% more than in 2020.

Financial Statements

Analyst Forecast

According to 17 analysts, the average rating for DCPH stock is "Buy." The 12-month stock price forecast is 19.02, which is an increase of 26.63% from the latest price.

Price Target
$19.02
(26.63% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities Hematology and Oncology Summit

WALTHAM, Mass.--( BUSINESS WIRE )--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a virtual fireside chat a...

4 days ago - Business Wire

Deciphera's (DCPH) Q3 Loss Narrows, Qinlock Drives Revenues

Deciphera (DCPH) reports a narrower-than-expected loss for the third quarter of 2022 while revenues beat estimates. Qinlock drives year-over-year sales.

1 month ago - Zacks Investment Research

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Tops Revenue Estimates

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 3.51% and 8.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for t...

1 month ago - Zacks Investment Research

Is Deciphera Pharmaceuticals (DCPH) Stock Outpacing Its Medical Peers This Year?

Here is how Deciphera Pharmaceuticals, Inc. (DCPH) and Jazz Pharmaceuticals (JAZZ) have performed compared to their sector so far this year.

2 months ago - Zacks Investment Research

Deciphera (DCPH) Rises 90% in the Past 6 Months: Here's Why

Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs.

2 months ago - Zacks Investment Research

Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT at the European Society for M...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve th...

2 months ago - Business Wire

Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inh...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve th...

2 months ago - Business Wire

Deciphera Pharmaceuticals, Inc. to Host Virtual Investor Event Featuring Key Opinion Leaders to Discuss DCC-3116 and ...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve th...

3 months ago - Business Wire

Deciphera (DCPH) Thrives on Qinlock, Overdependence a Concern

Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. However, heavy dependence on Qinlock for growth remains a woe.

3 months ago - Zacks Investment Research

Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve th...

3 months ago - Business Wire

Deciphera Pharmaceuticals, Inc. Announces Publication of INTRIGUE Phase 3 Clinical Study Results in Journal of Clinic...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve th...

3 months ago - Business Wire

Deciphera (DCPH) Loss Narrows in Q2, Qinlock Drive Revenues

Deciphera (DCPH) reports a narrower-than-expected loss in the second quarter of 2022 while revenues beat estimates. Shares rise.

4 months ago - Zacks Investment Research

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q2 Loss, Tops Revenue Estimates

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 7.69% and 7.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the st...

4 months ago - Zacks Investment Research

Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the...

4 months ago - Business Wire

Deciphera Pharmaceuticals, Inc. to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcas...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve th...

4 months ago - Business Wire

Does Deciphera Pharmaceuticals, Inc. (DCPH) Have the Potential to Rally 27% as Wall Street Analysts Expect?

The consensus price target hints at a 26.9% upside potential for Deciphera Pharmaceuticals, Inc. (DCPH). While empirical research shows that this sought-after metric is hardly effective, an upward trend...

4 months ago - Zacks Investment Research

Will Deciphera Pharmaceuticals, Inc. (DCPH) Report Negative Q2 Earnings? What You Should Know

Deciphera Pharmaceuticals, Inc. (DCPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Is Deciphera Pharmaceuticals (DCPH) Outperforming Other Medical Stocks This Year?

Here is how Deciphera Pharmaceuticals, Inc. (DCPH) and Evolus, Inc. (EOLS) have performed compared to their sector so far this year.

4 months ago - Zacks Investment Research

Has Deciphera Pharmaceuticals (DCPH) Outpaced Other Medical Stocks This Year?

Here is how Deciphera Pharmaceuticals, Inc. (DCPH) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year.

4 months ago - Zacks Investment Research

Deciphera Pharmaceuticals, Inc. Appoints Kelley Dealhoy as Chief Business Officer

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced the appointment of Kelley Dealhoy as Senior Vice President and Chief Business Officer. Ms. Dealhoy brings ...

5 months ago - Business Wire

Deciphera (DCPH) Up More Than 30% in Past 3 Months: Here's Why

Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs.

5 months ago - Zacks Investment Research

Deciphera Pharmaceuticals, Inc. (DCPH) Up 4.3% Since Last Earnings Report: Can It Continue?

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock?

6 months ago - Zacks Investment Research